Healthcare & Biotech

We have initiated coverage on CSL Limited (CSL) with a price target of $345 and a Buy recommendation.

NEU released impressive efficacy and safety results from the first of four single-arm Phase 2 trials evaluating NNZ-2591 (n=18).

The fundamentals and demographic trends for the healthcare and biotech sector remained strong in 2019 and we expect some of the key themes from this year to continue to play out in 2020.

The small to mid market cap biotech/healthcare section of the market has had a banner year in 2019 with numerous stocks enjoying the benefit of success in the clinic as well as regulatory and commercialisation success.